Neurophet to present brain stimulation simulation study at OHBM 2024
- Presents a poster identifying tDCS effects for patients with AD and cognitively normal people - Showcases brain imaging treatment planning software for electric brain stimulation Neurophet tESplan Plus SEOUL, South Korea, June 26, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that it presented research study...
bioSeedin Expanded Global Licensing and Partnership Opportunities at 2024 BIO International Convention
NEWARK, Del., June 26, 2024 /PRNewswire/ -- bioSeedin, a flourishing global licensing and consulting platform, captivated attendees as an esteemed exhibitor at the BIO International Convention, the preeminent global biotech gathering. This prestigious event unfolded in San Diego, spanning from June 3rd to June 6th, 2024, over the course of four enlightening days. At the distinguished four-day event, the...
Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer's disease showed more rapid clinical progression in biomarker-positive patients, highlighting the suitability of elevated pTau for selecting patients in the on-going XanaMIA phase 2b trial SYDNEY, June 26, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX:ACW) announces the peer-reviewed publication of its phase...
CARING PHARMACY UNVEILS MOM & CUTIE PRODUCT LINE IN CELEBRATORY 30TH ANNIVERSARY EVENT
KUALA LUMPUR, Malaysia, June 26, 2024 /PRNewswire/ -- CARiNG Pharmacy proudly celebrates its 30th anniversary with the grand launch of their 'Mom and Cutie' product line. To commemorate this milestone event, CARiNG Pharmacy held a Health & Beauty Carnival at 1 Utama Shopping Centre, Ground Floor Centre Court. The event was officiated by Mr Chong Yeow Siang; Managing Director...
Fufang E’jiao Syrup’s Breakthrough Research on Cancer-Related Fatigue Receives “Special Excellence Award” at 2024 ASCO Annual Meeting
CHICAGO, June 26, 2024 /PRNewswire/ -- The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), a significant event in the global oncology community, was grandly held in Chicago, USA, from May 31 to June 4, 2024. ASCO has announced the list of outstanding abstracts for 2024, which included 138 "Excellence Awards" and 5 "Special Excellence Awards."...
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). - The approval of XPOVIO® by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland...
Apollo Cancer Centres Collaborates With Accuray to Launch India Sub- Continent’s First Robotic Stereotactic Radiotherapy Program
The program will enhance the development of oncology care, thereby, advancing healthcare landscape of the region Participants will engage in in-depth discussions and demonstrations, ensuring a robust and practical learning experience BANGALORE, India, June 26, 2024 /PRNewswire/ -- Apollo Cancer Centres (ACC), in association with Accuray, a global provider of...
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EGFR) antibody drug developed in collaboration with Mabpharm Limited (2181.HK), has recently received approval from the China National Medical Administration...
Hyundai Bioscience succeeds in developing ‘Multi-treatment for mosquito-borne viral infections’ including Dengue Fever
Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted in Brazil. SEOUL, South Korea, June 26, 2024 /PRNewswire/ -- Hyundai Bioscience (CEO Oh...
Yoshihiro Yoneda Appointed President of the International Human Frontier Science Program Organization
STRASBOURG, France, June 26, 2024 /PRNewswire/ -- The International Human Frontier Science Program Organization (HFSPO) is pleased to announce that acclaimed Japanese cell biologist and international research leader Yoshihiro Yoneda will assume the role of President for the global life science organization. Yoshihiro Yoneda Appointed President of HFSPO "We...
